This example illustrates the evaluation of a population design for a one-compartment PK model with first-order absorption, defined analytically. Two covariates are considered:
The design consists of a single arm of 40 subjects, each receiving a single oral dose of 30 mg at time 0, sampled at 5 time points. The population FIM is evaluated, and a covariate test is run to assess the power to detect the covariate effects (significance, non-relevance, and equivalence tests).
The objective is to evaluate this design and how it assesses significance and non-relevance on the covariates, with the power for initial sample size and the number of subjects required to reach 90% power. Secondly, we aim to find the D-optimal design with only 3 sampling times, using possible sampling time windows and a continuous design space optimization. The number of subjects and the dosing regimen is unchanged. At the end, we aim to compare if this sparser optimal design leads to equivalent performances on covariate tests than the initial design.
Optimization results are computed by example03_execute.R
(run once, then cached as .RDS in data/). HTML
reports are written to results/. Reports are also available
at https://github.com/packagePFIM
The equation corresponds to a one-compartment model with first-order
absorption, with parameters ka, V and Cl. The dose is passed via the
dose_RespPK keyword.
The model has three structural parameters, all log-normally distributed. Inter-individual variability (\(\omega\)) and inter-occasion variability (\(\gamma\)) are specified for each.
| Parameter | Description | \(\mu\) | \(\omega\) | \(\gamma\) | Fixed \(\mu\) | Fixed \(\omega\) |
|---|---|---|---|---|---|---|
| ka | Absorption rate constant (h\(^{-1}\)) | 1 | \(\sqrt{0.09} \approx 0.30\) | \(\sqrt{0.0225} = 0.15\) | No | No |
| V | Volume of distribution (L) | 3.5 | \(\sqrt{0.09} \approx 0.30\) | \(\sqrt{0.0225} = 0.15\) | No | No |
| Cl | Elimination clearance (L/h) | 2 | \(\sqrt{0.09} \approx 0.30\) | \(\sqrt{0.0225} = 0.15\) | No | No |
modelParameters = list(
ModelParameter( name = "ka", distribution = LogNormal( mu = 1, omega = sqrt(0.09) ), gamma = sqrt(0.0225) ),
ModelParameter( name = "V", distribution = LogNormal( mu = 3.5, omega = sqrt(0.09) ), gamma = sqrt(0.0225) ),
ModelParameter( name = "Cl", distribution = LogNormal( mu = 2, omega = sqrt(0.09) ), gamma = sqrt(0.0225) )
)A constant (additive) residual error model is used, with
sigmaInter = 0.1 (variance = 0.01).
Covariate effects are parameterised on the log scale
(modelCovariatesEquation = "exponential"), so each \(\beta\) coefficient represents the
log-ratio of the affected parameter between the non-reference and the
reference category.
| Covariate | Type | Categories | Proportions | Affected parameter | Effect (\(\beta\)) | Reference |
|---|---|---|---|---|---|---|
| Sex | Between-subject (fixed) | M / F | 50 % / 50 % | V | log(1.2) \(\approx\) 0.182 | M |
| Treatment | Within-subject (occasion) | R / T | 50 % / 50 % | Cl | log(1.1) \(\approx\) 0.095 | R |
Sex is a between-subject covariate with an
exponential effect on V. The log-ratio between female and
male typical values is log(1.2).
sex = Covariate(
name = "Sex",
categories = c("M", "F"),
categoriesProportions = c(0.5, 0.5),
effects = list( "F" = c( "V" = log(1.2) ) )
)Treatment is a within-subject (occasion) covariate
following a two-sequence, two-period crossover design. The log-ratio of
clearance under treatment T relative to treatment R is
log(1.1).
A single oral dose of 30 mg is administered at time 0. Five sampling times are specified to cover both the absorption and elimination phases.
A single arm of 40 subjects on the same regimen.
The covariate effects use an exponential parameterisation
(modelCovariatesEquation = "exponential"). The analytic
model does not require ODE solver parameters.
evaluationPop = Evaluation(
name = "",
modelParameters = modelParameters,
modelCovariates = list( sex, treatment ),
modelCovariatesEquation = "exponential",
modelEquations = modelEquations,
modelError = modelError,
designs = list( design1 ),
fimType = "population",
outputs = list( "RespPK" = "RespPK" )
)
evaluationPopFIM = run( evaluationPop )
***************************************
Population Fisher Matrix
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
μ_ka 339.888866 -12.1244029 2.2403232 -17.9762700 1.8294873 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_V -12.124403 29.3831440 0.5085979 52.3319426 0.4561115 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_Cl 2.240323 0.5085979 98.2790307 0.8587853 98.1435338 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_V_Sex_F -17.976270 52.3319426 0.8587853 183.1617992 0.8270805 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_Cl_Treatment_T 1.829487 0.4561115 98.1435338 0.8270805 953.4932901 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
ω²_ka 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 1444.4800032 2.303490e+01 2.509671e-01 7.250348e+02 1.529776e+01 1.301725e-01 423.70188
ω²_V 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 23.0348957 1.620000e+03 1.586320e-01 1.385535e+01 8.131879e+02 8.052141e-02 269.48022
ω²_Cl 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 0.2509671 1.586320e-01 1.931754e+03 1.290869e-01 9.016087e-02 9.658788e+02 18.52264
γ²_ka 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 725.0347675 1.385535e+01 1.290869e-01 1.201459e+04 4.448247e+03 4.969634e+01 2591.78367
γ²_V 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 15.2977604 8.131879e+02 9.016087e-02 4.448247e+03 1.990898e+04 3.195887e+01 1814.53482
γ²_Cl 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 0.1301725 8.052141e-02 9.658788e+02 4.969634e+01 3.195887e+01 3.707617e+04 615.30442
σ_inter_RespPK 0.000000 0.0000000 0.0000000 0.0000000 0.0000000 423.7018815 2.694802e+02 1.852264e+01 2.591784e+03 1.814535e+03 6.153044e+02 36667.05676
***************************************
Fixed effects (μ)
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T
μ_ka 339.888866 -12.1244029 2.2403232 -17.9762700 1.8294873
μ_V -12.124403 29.3831440 0.5085979 52.3319426 0.4561115
μ_Cl 2.240323 0.5085979 98.2790307 0.8587853 98.1435338
β_V_Sex_F -17.976270 52.3319426 0.8587853 183.1617992 0.8270805
β_Cl_Treatment_T 1.829487 0.4561115 98.1435338 0.8270805 953.4932901
***************************************
Variance components (ω², γ², σ)
***************************************
ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
ω²_ka 1444.4800032 2.303490e+01 2.509671e-01 7.250348e+02 1.529776e+01 1.301725e-01 423.70188
ω²_V 23.0348957 1.620000e+03 1.586320e-01 1.385535e+01 8.131879e+02 8.052141e-02 269.48022
ω²_Cl 0.2509671 1.586320e-01 1.931754e+03 1.290869e-01 9.016087e-02 9.658788e+02 18.52264
γ²_ka 725.0347675 1.385535e+01 1.290869e-01 1.201459e+04 4.448247e+03 4.969634e+01 2591.78367
γ²_V 15.2977604 8.131879e+02 9.016087e-02 4.448247e+03 1.990898e+04 3.195887e+01 1814.53482
γ²_Cl 0.1301725 8.052141e-02 9.658788e+02 4.969634e+01 3.195887e+01 3.707617e+04 615.30442
σ_inter_RespPK 423.7018815 2.694802e+02 1.852264e+01 2.591784e+03 1.814535e+03 6.153044e+02 36667.05676
*********************************************
Determinant, condition numbers and D-criterion
***********************************************
Determinant: 9.179643e+37
D-criterion: 1457.367
Condition number (fixed effects): 73.40657
Condition number (variance components): 27.34871
***************************************
Parameters estimation
***************************************
Parameter Value SE RSE(%)
μ_ka 1.00000000 0.054662025 5.466202
μ_V 3.50000000 0.264574919 7.559283
μ_Cl 2.00000000 0.106506758 5.325338
β_V_Sex_F 0.18232156 0.105457033 57.841231
β_Cl_Treatment_T 0.09531018 0.034189595 35.871924
ω²_ka 0.09000000 0.026779506 29.755007
ω²_V 0.09000000 0.025141327 27.934808
ω²_Cl 0.09000000 0.022901883 25.446537
γ²_ka 0.02250000 0.009744927 43.310785
γ²_V 0.02250000 0.007496871 33.319425
γ²_Cl 0.02250000 0.005228287 23.236831
σ_inter_RespPK 0.10000000 0.005272574 5.272574
***************************************
Legend:
μ = fixed effects (population means)
β = covariate effects
ω² = inter-individual variability (IIV)
γ² = inter-occasion variability (IOV)
σ = residual error SD
***************************************
[1] 1457.367
plotsSI = plotSensitivityIndices( evaluationPopFIM, plotOptions )
print( plotsSI$design1$arm1$RespPK$V )outputFile = "vignette3_evaluation_popFim_report.html"
Report(evaluationPopFIM, paths$reports, outputFile, plotOptions)Of note, we could also use these functions to extract specific results:
The covariateTest function computes power for three
hypothesis testing frameworks:
\(\Delta\) is conventionally set to \(\log(1.25) \approx 0.223\).
============================================================
Statistical significance (β, bilateral Wald test)
Target power: 90% | Current sample size N = 40
============================================================
Parameter Value SE RSE Power N_Required
β_V_Sex_F 0.1823 0.1055 57.84 40.9 141
β_Cl_Treatment_T 0.0953 0.0342 35.87 79.6 55
============================================================
Clinical non-relevance (TOST on β)
Target power: 90% | Current sample size N = 40 | Equivalence IC (90%) on ratio: [0.80, 1.25]
============================================================
Parameter Value SE RSE Ratio IC_Inf IC_Sup Power N_Required
β_V_Sex_F 0.1823 0.1055 57.84 1.2 1.0089 1.4273 9.0 2287
β_Cl_Treatment_T 0.0953 0.0342 35.87 1.1 1.0398 1.1636 98.2 25
============================================================
Clinical relevance (β outside equivalence bounds)
Target power: 90% | Current sample size N = 40 | Equivalence IC (90%) on ratio: [0.80, 1.25]
============================================================
(none)
Both optimization algorithms share the same model, error, covariates, and covariate equation as the evaluation step. Only the arm definition and the optimizer-specific parameters differ between the two approaches. The goal is to reduce the design to 3 sampling times while maximising the D-criterion of the population FIM.
The Multiplicative Algorithm operates over a discrete candidate set: at each iteration it reweights a probability distribution over elementary designs (one per candidate time point) and prunes those with negligible weight. It is well-suited when the candidate set is finite and moderate in size.
The dose is fixed at 30 mg. Three of the five candidate sampling times are left optimizable; no windows are imposed, so the algorithm selects freely among \(\{0.5, 2, 4, 6, 8\}\) h.
The arm carries both administrationsConstraints and
samplingTimesConstraints. The full set of candidate times
is used as the initial sampling grid.
armMult = Arm( name = "armOpt",
size = 40,
administrations = list( administrationRespPK ),
samplingTimes = list( samplingTimesRespPK ),
administrationsConstraints = list( administrationConstraintsRespPK ),
samplingTimesConstraints = list( samplingConstraintsRespPK ) )
designMult = Design( name = "design1", arms = list( armMult ) )optimizationMult = Optimization(
name = "Multiplicative",
modelEquations = modelEquations,
modelParameters = modelParameters,
modelCovariates = list( treatment, sex ),
modelCovariatesEquation = "exponential",
numberOfOccasions = 2,
modelError = modelError,
optimizer = "MultiplicativeAlgorithm",
optimizerParameters = list( lambda = 0.99,
numberOfIterations = 1000,
weightThreshold = 0.01,
delta = 1e-04,
showProcess = TRUE ),
designs = list( designMult ),
fimType = "population",
outputs = list( "RespPK" = "RespPK" )
)
--- Optimal design ---
Arms name Number of subjects Outcome Dose Sampling times
1 Arm2 40 RespPK 30 (0.5, 2, 6)
***************************************
Population Fisher Matrix
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
μ_ka 329.525019 -14.8691159 3.6912288 -22.229595 3.834115 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_V -14.869116 28.6258030 0.9910258 51.227048 1.140631 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_Cl 3.691229 0.9910258 97.7403300 1.572171 97.536153 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_V_Sex_F -22.229595 51.2270485 1.5721714 179.294670 1.950838 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_Cl_Treatment_T 3.834115 1.1406306 97.5361532 1.950838 921.108493 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
ω²_ka 0.000000 0.0000000 0.0000000 0.000000 0.000000 1357.8361091 34.5732189 0.6847072 6.813632e+02 2.154327e+01 3.442112e-01 471.21810
ω²_V 0.000000 0.0000000 0.0000000 0.000000 0.000000 34.5732189 1537.8685240 0.6068128 1.953730e+01 7.728726e+02 3.116263e-01 318.44875
ω²_Cl 0.000000 0.0000000 0.0000000 0.000000 0.000000 0.6847072 0.6068128 1910.6360130 3.574753e-01 3.591748e-01 9.553226e+02 37.92596
γ²_ka 0.000000 0.0000000 0.0000000 0.000000 0.000000 681.3632370 19.5373025 0.3574753 1.110686e+04 5.046391e+03 7.411171e+01 2362.92816
γ²_V 0.000000 0.0000000 0.0000000 0.000000 0.000000 21.5432660 772.8726445 0.3591748 5.046391e+03 1.814370e+04 1.153055e+02 1743.34778
γ²_Cl 0.000000 0.0000000 0.0000000 0.000000 0.000000 0.3442112 0.3116263 955.3226353 7.411171e+01 1.153055e+02 3.441060e+04 1139.56787
σ_inter_RespPK 0.000000 0.0000000 0.0000000 0.000000 0.000000 471.2181022 318.4487533 37.9259602 2.362928e+03 1.743348e+03 1.139568e+03 5510.31205
***************************************
Fixed effects (μ)
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T
μ_ka 329.525019 -14.8691159 3.6912288 -22.229595 3.834115
μ_V -14.869116 28.6258030 0.9910258 51.227048 1.140631
μ_Cl 3.691229 0.9910258 97.7403300 1.572171 97.536153
β_V_Sex_F -22.229595 51.2270485 1.5721714 179.294670 1.950838
β_Cl_Treatment_T 3.834115 1.1406306 97.5361532 1.950838 921.108493
***************************************
Variance components (ω², γ², σ)
***************************************
ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
ω²_ka 1357.8361091 34.5732189 0.6847072 6.813632e+02 2.154327e+01 3.442112e-01 471.21810
ω²_V 34.5732189 1537.8685240 0.6068128 1.953730e+01 7.728726e+02 3.116263e-01 318.44875
ω²_Cl 0.6847072 0.6068128 1910.6360130 3.574753e-01 3.591748e-01 9.553226e+02 37.92596
γ²_ka 681.3632370 19.5373025 0.3574753 1.110686e+04 5.046391e+03 7.411171e+01 2362.92816
γ²_V 21.5432660 772.8726445 0.3591748 5.046391e+03 1.814370e+04 1.153055e+02 1743.34778
γ²_Cl 0.3442112 0.3116263 955.3226353 7.411171e+01 1.153055e+02 3.441060e+04 1139.56787
σ_inter_RespPK 471.2181022 318.4487533 37.9259602 2.362928e+03 1.743348e+03 1.139568e+03 5510.31205
*********************************************
Determinant, condition numbers and D-criterion
***********************************************
Determinant: 6.99616e+36
D-criterion: 1175.994
Condition number (fixed effects): 73.62066
Condition number (variance components): 27.12185
***************************************
Parameters estimation
***************************************
Parameter Value SE RSE(%)
μ_ka 1.00000000 0.055779755 5.577975
μ_V 3.50000000 0.269550251 7.701436
μ_Cl 2.00000000 0.107001337 5.350067
β_V_Sex_F 0.18232156 0.106866965 58.614553
β_Cl_Treatment_T 0.09531018 0.034841408 36.555810
ω²_ka 0.09000000 0.027873726 30.970807
ω²_V 0.09000000 0.025956084 28.840093
ω²_Cl 0.09000000 0.023038148 25.597942
γ²_ka 0.02250000 0.010667716 47.412069
γ²_V 0.02250000 0.008076677 35.896343
γ²_Cl 0.02250000 0.005448899 24.217327
σ_inter_RespPK 0.10000000 0.014423557 14.423557
***************************************
Legend:
μ = fixed effects (population means)
β = covariate effects
ω² = inter-individual variability (IIV)
γ² = inter-occasion variability (IOV)
σ = residual error SD
***************************************
[1] 1175.994
The Simplex (Nelder-Mead) algorithm is a derivative-free local optimizer that searches over a continuous design space. It is more flexible than the Multiplicative algorithm but sensitive to the starting point and may converge to a local optimum.
Three sampling times are optimized continuously within \([0, 8]\) h, with a minimum spacing of 0.5 h
between consecutive samples (minSampling). The initial
design \(\{0.5, 4, 8\}\) h seeds the
starting simplex.
No administration constraints are needed here since the dose is fixed. The arm uses the Simplex-specific initial samplings and constraints.
optimizationSimplex = Optimization(
name = "Simplex",
modelEquations = modelEquations,
modelParameters = modelParameters,
modelCovariates = list( treatment, sex ),
modelCovariatesEquation = "exponential",
modelError = modelError,
optimizer = "SimplexAlgorithm",
optimizerParameters = list( pctInitialSimplexBuilding = 20,
maxIteration = 200,
tolerance = 1e-6,
showProcess = TRUE ),
designs = list( designSimplex ),
fimType = "population",
outputs = list( "RespPK" = "RespPK" )
)
--- Optimal design ---
Arms name Number of subjects Outcome Dose Sampling times
1 armOpt 40 RespPK 30 (0.44, 2.12, 5.86)
***************************************
Population Fisher Matrix
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
μ_ka 330.439745 -14.7495376 3.8038395 -21.980586 3.5060207 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_V -14.749538 28.6089272 0.9876018 51.204431 0.9983358 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
μ_Cl 3.803840 0.9876018 97.8118620 1.614347 97.6747350 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_V_Sex_F -21.980586 51.2044310 1.6143474 179.215508 1.7737472 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
β_Cl_Treatment_T 3.506021 0.9983358 97.6747350 1.773747 926.7816150 0.0000000 0.0000000 0.0000000 0.000000e+00 0.000000e+00 0.000000e+00 0.00000
ω²_ka 0.000000 0.0000000 0.0000000 0.000000 0.0000000 1365.3935336 34.0460374 0.7245992 6.851897e+02 2.128161e+01 3.663988e-01 466.02497
ω²_V 0.000000 0.0000000 0.0000000 0.000000 0.0000000 34.0460374 1536.0663676 0.6000035 1.933685e+01 7.720054e+02 3.020143e-01 321.07135
ω²_Cl 0.000000 0.0000000 0.0000000 0.000000 0.0000000 0.7245992 0.6000035 1913.4339006 3.743861e-01 3.421471e-01 9.567191e+02 35.06315
γ²_ka 0.000000 0.0000000 0.0000000 0.000000 0.0000000 685.1897079 19.3368484 0.3743861 1.124511e+04 4.986075e+03 8.824822e+01 2378.03245
γ²_V 0.000000 0.0000000 0.0000000 0.000000 0.0000000 21.2816084 772.0053609 0.3421471 4.986075e+03 1.789745e+04 1.079444e+02 1802.97824
γ²_Cl 0.000000 0.0000000 0.0000000 0.000000 0.0000000 0.3663988 0.3020143 956.7190716 8.824822e+01 1.079444e+02 3.486307e+04 1041.15299
σ_inter_RespPK 0.000000 0.0000000 0.0000000 0.000000 0.0000000 466.0249713 321.0713506 35.0631508 2.378032e+03 1.802978e+03 1.041153e+03 5472.27695
***************************************
Fixed effects (μ)
***************************************
μ_ka μ_V μ_Cl β_V_Sex_F β_Cl_Treatment_T
μ_ka 330.439745 -14.7495376 3.8038395 -21.980586 3.5060207
μ_V -14.749538 28.6089272 0.9876018 51.204431 0.9983358
μ_Cl 3.803840 0.9876018 97.8118620 1.614347 97.6747350
β_V_Sex_F -21.980586 51.2044310 1.6143474 179.215508 1.7737472
β_Cl_Treatment_T 3.506021 0.9983358 97.6747350 1.773747 926.7816150
***************************************
Variance components (ω², γ², σ)
***************************************
ω²_ka ω²_V ω²_Cl γ²_ka γ²_V γ²_Cl σ_inter_RespPK
ω²_ka 1365.3935336 34.0460374 0.7245992 6.851897e+02 2.128161e+01 3.663988e-01 466.02497
ω²_V 34.0460374 1536.0663676 0.6000035 1.933685e+01 7.720054e+02 3.020143e-01 321.07135
ω²_Cl 0.7245992 0.6000035 1913.4339006 3.743861e-01 3.421471e-01 9.567191e+02 35.06315
γ²_ka 685.1897079 19.3368484 0.3743861 1.124511e+04 4.986075e+03 8.824822e+01 2378.03245
γ²_V 21.2816084 772.0053609 0.3421471 4.986075e+03 1.789745e+04 1.079444e+02 1802.97824
γ²_Cl 0.3663988 0.3020143 956.7190716 8.824822e+01 1.079444e+02 3.486307e+04 1041.15299
σ_inter_RespPK 466.0249713 321.0713506 35.0631508 2.378032e+03 1.802978e+03 1.041153e+03 5472.27695
*********************************************
Determinant, condition numbers and D-criterion
***********************************************
Determinant: 7.158466e+36
D-criterion: 1178.243
Condition number (fixed effects): 74.1044
Condition number (variance components): 27.29803
***************************************
Parameters estimation
***************************************
Parameter Value SE RSE(%)
μ_ka 1.00000000 0.055691378 5.569138
μ_V 3.50000000 0.269619463 7.703413
μ_Cl 2.00000000 0.106939190 5.346960
β_V_Sex_F 0.18232156 0.106899271 58.632272
β_Cl_Treatment_T 0.09531018 0.034726340 36.435079
ω²_ka 0.09000000 0.027786365 30.873739
ω²_V 0.09000000 0.025974156 28.860173
ω²_Cl 0.09000000 0.023019434 25.577148
γ²_ka 0.02250000 0.010580034 47.022372
γ²_V 0.02250000 0.008124777 36.110122
γ²_Cl 0.02250000 0.005409441 24.041960
σ_inter_RespPK 0.10000000 0.014478141 14.478141
***************************************
Legend:
μ = fixed effects (population means)
β = covariate effects
ω² = inter-individual variability (IIV)
γ² = inter-occasion variability (IOV)
σ = residual error SD
***************************************
[1] 1178.243
optimisationDesign = prop( optimizationSimplexPopFIM, "optimisationDesign" )
evaluationOptimalDesign = optimisationDesign$evaluationOptimalDesign
optimalTests = covariateTest( evaluationOptimalDesign )
show( optimalTests )
============================================================
Statistical significance (β, bilateral Wald test)
Target power: 90% | Current sample size N = 40
============================================================
Parameter Value SE RSE Power N_Required
β_V_Sex_F 0.1823 0.1069 58.63 40.0 145
β_Cl_Treatment_T 0.0953 0.0347 36.44 78.4 56
============================================================
Clinical non-relevance (TOST on β)
Target power: 90% | Current sample size N = 40 | Equivalence IC (90%) on ratio: [0.80, 1.25]
============================================================
Parameter Value SE RSE Ratio IC_Inf IC_Sup Power N_Required
β_V_Sex_F 0.1823 0.1069 58.63 1.2 1.0065 1.4307 8.7 2350
β_Cl_Treatment_T 0.0953 0.0347 36.44 1.1 1.0389 1.1647 97.9 26
============================================================
Clinical relevance (β outside equivalence bounds)
Target power: 90% | Current sample size N = 40 | Equivalence IC (90%) on ratio: [0.80, 1.25]
============================================================
(none)
Using 3-point optimal design leads to only a slight loss of power, with N = 145 subjects required to achieve 90% power on the significance of the sex effect on V, instead of N = 141 on 5-point initial design. It also requires N = 26 subjects to assess clinical non-relevance of the treatment on Cl with 90% power, instead of N = 25 on 5-point initial design.